nach oben

Erschienen in:

01.11.2012 | Original Article

Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study

verfasst von: Patrizia Ferroni, Francesca Martini, Ilaria Portarena, Italia Grenga, Silvia Riondino, Francesca La Farina, Anastasia Laudisi, Fiorella Guadagni, Mario Roselli

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Identifying cancer patients who are most at risk for venous thromboembolism (VTE) is essential to improve timely delivery of chemotherapy. Several studies have been performed to identify novel candidate biomarkers, but no agreement has yet been reached. In this light, we sought to analyze whether a dynamic evaluation of early changes of activated protein C (APC) function during chemotherapy could be predictive of a first VTE episode in cancer outpatients, thus improving risk stratification.

Methods

A retrospective single-center pilot study was conducted to investigate the adequacy of a dynamic evaluation of a novel APC-dependent thrombin generation assay (HemosIL ThromboPath (ThP)) in predicting VTE in 208 ambulatory cancer patients, enrolled on the basis of tight inclusion criteria, prior to start and before the second cycle of a new chemotherapy regimen.

Results

Retrospective analysis of samples showed the occurrence of an acquired APC resistance during chemotherapy, which was predictive of VTE. Univariate Cox proportional hazards survival analysis showed that early ThP changes predicted VTE (stable vs. decreasing ThP: hazard ratio (HR) 0.21; 95% CI 0.10–0.19; p < 0.0001), which was confirmed in the multivariate model (HR 0.25; CI 0.12–0.52, p < 0.0001). Stratification of patients according to a risk assessment model showed a 0.18 HR for stable vs. decreasing ThP assay results in an intermediate risk group.

Conclusions

We may thus conclude that early changes of ThP assay in patients on active chemotherapy enhance VTE risk stratification, helping in identifying a population of cancer patients who might benefit from thromboprophylaxis.

Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118(5):555–568PubMedCrossRef

Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839–4847PubMedCrossRef

Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Büller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104(5):1049–1054PubMedCrossRef

Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3):529–535PubMedCrossRef

Feffer SE, Carmosino LS, Fox RL (1989) Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 63(7):1303–1307PubMedCrossRef

Sousou T, Khorana AA (2009) New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 29(3):316–320PubMedCrossRef

Ferroni P, Formica V, Roselli M, Guadagni F (2010) Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 8(1):102–113PubMedCrossRef

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, on behalf of the PROTECHT Investigators (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943–949PubMedCrossRef

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edn.). Chest 133(6 Suppl):381S–453S

10.

Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505PubMedCrossRef

11.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27(29):4919–4926PubMedCrossRef

12.

Mandalà M, Falanga A, Roila F, On behalf of the ESMO Guidelines Working Group (2010) Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 21(Suppl 5):v274–v276PubMedCrossRef

13.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907PubMedCrossRef

14.

Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703–2708PubMedCrossRef

15.

Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I (2009) D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27(25):4124–4129PubMedCrossRef

16.

Agterof MJ, van Bladel ER, Schutgens RE, Snijder RJ, Tromp EA, Prins MH, Biesma DH (2009) Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration. Thromb Haemost 102(4):683–687PubMed

17.

Douma RA, van Sluis GL, Kamphuisen PW, Söhne M, Leebeek FW, Bossuyt PM, Büller HR (2010) Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 104(4):831–836PubMedCrossRef

18.

Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Roselli M, Guadagni F (2011) An APC-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 105(5):931–932PubMedCrossRef

19.

Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Schirru M, Laudisi A, Roselli M, Guadagni F (2010) Association between increased tumor necrosis factor-alpha levels and impaired functionality of the protein C anticoagulant pathway in patients with metastatic colorectal cancer. Pathophysiol Haemost Thromb 37(Suppl 1):A107

20.

Elice F, Fink L, Tricot G, Barlogie B, Zangari M (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134(4):399–405PubMedCrossRef

21.

Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I (2004) Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15(11):1622–1626PubMedCrossRef

22.

Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, Lydataki N (2002) Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32(1):2–7PubMedCrossRef

23.

Negaard HF, Iversen PO, Østenstad B, Mowinckel MC, Sandset PM (2008) Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 6(9):1482–1487PubMedCrossRef

24.

Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, Tripodi A (2009) A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 124(1):137–143PubMedCrossRef

25.

Lewis MR, Callas PW, Jenny NS, Tracy RP (2001) Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 86(6):1495–1500PubMed

26.

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 21(4):871–876PubMedCrossRef

27.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382PubMedCrossRef

28.

Lyman GH (2009) Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 115(24):5637–5650PubMedCrossRef

29.

Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, Kauschat-Brüning D, Bramlage P, Dörken B, Oettle H (2008) Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 8:361PubMedCrossRef

30.

Maraveyas A, Waters J, Roy R, Propper D, Fyfe D, Lofts F, Gardiner E, Sgouros J, Wedgwood K (2009) Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Suppl 7:362CrossRef

31.

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339–2346PubMedCrossRef

32.

Noble S (2009) A step in the right direction, but one size might not fit all. Lancet Oncol 10(10):930–931PubMedCrossRef

33.

Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3):356–361PubMedCrossRef

34.

Pabinger I, Ay C (2009) Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 29(3):332–336PubMedCrossRef

35.

Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29(15):2099–2103PubMedCrossRef

36.

Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, Mannucci PM (2010) Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 30(2):215–219PubMedCrossRef

37.

Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW (2005) D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost 94(6):1312–1317PubMed

Titel: Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study
verfasst von: Patrizia Ferroni
Francesca Martini
Ilaria Portarena
Italia Grenga
Silvia Riondino
Francesca La Farina
Anastasia Laudisi
Fiorella Guadagni
Mario Roselli
Publikationsdatum: 01.11.2012
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1391-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2012

Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care

Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice

Symptom clusters in patients with bone metastases—a reanalysis comparing different statistical methods

Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting

Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival

Pharmaceutical care for patients with breast and ovarian cancer

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie